PerkinElmer Extends Clinical Whole Genome Sequencing Services
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, expanded its Whole Genome Sequencing (WGS) services to families that preserve their cord blood and cord tissue with ViaCord. This launch follows the Company’s recent introduction of its clinical WGS services.
Parents that choose ViaCord, PerkinElmer’s cord blood and cord tissue preservation business, now have the opportunity to benefit from a physician-ordered WGS test of their child’s DNA via a simple saliva test. The test examines a broad range of disease-related genes and provides diagnostic findings contributing to pediatric onset diseases. Additionally, the test reports on pharmacogenetic variants used to optimize certain drug selection.
“WGS is another great opportunity for families to identify and prepare for important health concerns, positioning themselves to benefit from the fast moving area of personalized medicine,” said Morey Kraus, chief scientific officer, ViaCord. “We have seen tremendous progress using cord blood stem cells to treat disease, and I expect families who make such health conscious decisions to benefit from WGS as well. Additionally, with the rapid progress we’ve seen with regenerative medicine and gene editing, insights from WGS may be used in the future, in combination with a family’s cord blood and cord tissue, to optimize the design of a treatment plan. This is a very exciting next new step in advancing personalized medicine.”
ViaCord has preserved the umbilical cord stem cells of more than 350,000 newborns and released over 360 cord blood units for treatment and clinical research studies. It has released more than 200 cord blood units for use in the treatment of nearly 80 diseases including acute lymphoblastic leukemia and sickle cell disease and more than 150 cord blood units for use in clinical research studies including for Cerebral Palsy and Autism Spectrum Disorder.
About PerkinElmer
PerkinElmer, Inc. is a global leader
committed to innovating for a healthier world. Our dedicated team of
9,000 employees worldwide is passionate about providing customers with
an unmatched experience as they help solve critical issues especially
impacting the diagnostics, discovery and analytical solutions markets.
Our innovative detection, imaging, informatics and service capabilities,
combined with deep market knowledge and expertise, help customers gain
earlier and more accurate insights to improve lives and the world around
us. The Company reported revenue of approximately $2.1 billion in 2016,
serves customers in more than 150 countries, and is a component of the
S&P 500 Index. Additional information is available through
1-877-PKI-NYSE, or at www.perkinelmer.com.
Factors Affecting Future Performance
This press release contains
"forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not limited to,
statements relating to estimates and projections of future earnings per
share, cash flow and revenue growth and other financial results,
developments relating to our customers and end-markets, and plans
concerning business development opportunities and divestitures. Words
such as "believes," "intends," "anticipates," "plans," "expects,"
"projects," "forecasts," "will" and similar expressions, and references
to guidance, are intended to identify forward-looking statements. Such
statements are based on management's current assumptions and
expectations and no assurances can be given that our assumptions or
expectations will prove to be correct. A number of important risk
factors could cause actual results to differ materially from the results
described, implied or projected in any forward-looking statements. These
factors include, without limitation: (1) markets into which we sell our
products declining or not growing as anticipated; (2) fluctuations in
the global economic and political environments; (3) our failure to
introduce new products in a timely manner; (4) our ability to execute
acquisitions and license technologies, or to successfully integrate
acquired businesses and licensed technologies into our existing business
or to make them profitable, or successfully divest businesses; (5) our
failure to adequately protect our intellectual property; (6) the loss of
any of our licenses or licensed rights; (7) our ability to compete
effectively; (8) fluctuation in our quarterly operating results and our
ability to adjust our operations to address unexpected changes; (9)
significant disruption in third-party package delivery and import/export
services or significant increases in prices for those services; (10)
disruptions in the supply of raw materials and supplies; (11) the
manufacture and sale of products exposing us to product liability
claims; (12) our failure to maintain compliance with applicable
government regulations; (13) regulatory changes; (14) our failure to
comply with healthcare industry regulations; (15) economic, political
and other risks associated with foreign operations; (16) our ability to
retain key personnel; (17) significant disruption in our information
technology systems; (18) our ability to obtain future financing; (19)
restrictions in our credit agreements; (20) the approval of the Brexit
Referendum in the United Kingdom; (21) our ability to realize the full
value of our intangible assets; (22) significant fluctuations in our
stock price; (23) reduction or elimination of dividends on our common
stock; and (24) other factors which we describe under the caption "Risk
Factors" in our most recent quarterly report on Form 10-Q and in our
other filings with the Securities and Exchange Commission. We disclaim
any intention or obligation to update any forward-looking statements as
a result of developments occurring after the date of this press release.
PerkinElmer, Inc.
Brian Willinsky, +1-781-663-5728
brian.willinsky@perkinelmer.com